One of the questions cardiologists hear surprisingly often is:
“My cholesterol was normal. How did I end up with a major heart blockage?”
It is a very reasonable question.
For years, many people have thought of a cholesterol test almost as a pass-or-fail examination for heart disease. If the numbers were “normal,” they assumed their arteries must be normal too.
Unfortunately, it doesn’t work that way.
A standard cholesterol panel is important. But cholesterol is only one part of cardiovascular risk. Genetics, diabetes, the number of cholesterol-carrying particles in the blood, inflammation, blood pressure, smoking and family history can all change the picture.
And there is an even more important distinction:
Blood tests can help us estimate your risk of developing coronary artery disease. They cannot tell us whether a particular artery is actually narrowed or blocked.
That distinction is worth understanding.
The 30-second version
If you remember only five things from this article, remember these:
- A normal cholesterol report does not prove that your coronary arteries are normal.
- Every adult should now have Lipoprotein(a), or Lp(a), checked at least once.
- ApoB can sometimes identify risk that LDL cholesterol misses.
- Blood sugar and, in selected patients, inflammation matter too.
- No blood test can tell you whether you have a 70%, 90% or 100% coronary blockage.
Let us look at the tests that actually matter.
1. The Standard Lipid Panel: Still the Starting Point
Despite all the newer tests available today, the basic lipid panel remains extremely useful.
It usually includes:
- LDL cholesterol
- HDL cholesterol
- triglycerides
- total cholesterol
You may also see non-HDL cholesterol, which is calculated from the same test and captures cholesterol carried by several potentially atherogenic particles.
What does a high LDL actually mean?
LDL-C measures the amount of cholesterol carried within LDL particles.
Over time, exposure to high levels of these atherogenic particles promotes cholesterol deposition within the artery wall and contributes to atherosclerosis.
But a high LDL does not mean:
“I have a blockage today.”
It means your long-term probability of developing atherosclerotic disease is higher unless that risk is appropriately addressed.
The reverse is equally important.
A reasonably good LDL level does not guarantee that you do not already have coronary disease.
If you already have coronary artery disease
The targets become much more aggressive.
The 2026 ACC/AHA dyslipidemia guideline recommends an LDL-C goal below 55 mg/dL for patients at very high risk from established atherosclerotic cardiovascular disease. A smaller group with established disease who are not considered very high risk may have a goal below 70 mg/dL.
The important point is that once somebody has established coronary disease, we are no longer talking simply about having cholesterol within the laboratory’s “normal range.”
We are trying to reduce future cardiovascular events.
2. Lipoprotein(a): The Blood Test Many Adults Have Never Had
If there is one blood test I would like more people to know about, it is Lipoprotein(a), usually written as Lp(a).
Lp(a) is an LDL-like particle, but it behaves differently from ordinary LDL.
Most importantly, your Lp(a) level is largely inherited.
That means someone can:
- exercise regularly,
- eat reasonably well,
- have a satisfactory conventional cholesterol result,
and still have a significantly elevated Lp(a).
Lifestyle remains extremely important for overall cardiovascular health, but diet and exercise generally have relatively little effect on the Lp(a) level itself.
Who should have it checked?
This is one of the major changes in contemporary cardiovascular prevention.
The 2026 ACC/AHA guideline recommends that every adult have Lp(a) measured at least once.
Because the level is largely genetically determined and generally remains fairly stable, one good measurement will often be sufficient.
What number is considered high?
An Lp(a) level of:
≥125 nmol/L OR ≥50 mg/dL
is considered a cardiovascular risk-enhancing level.
It is better to use the units reported by your laboratory rather than trying to mathematically convert mg/dL into nmol/L, because there is no perfectly accurate universal conversion between the two.
What does a high Lp(a) mean?
It means:
Your inherited lifetime risk of atherosclerotic cardiovascular disease is higher than your conventional cholesterol panel alone may suggest.
It does not mean you definitely have a coronary blockage today.
If Lp(a) is high, the practical response is usually to become more rigorous about the things we can modify—particularly LDL cholesterol, blood pressure, diabetes, smoking, weight and lifestyle.
There is also an important family implication.
Because Lp(a) is inherited, a significantly elevated level is a reason for first-degree relatives to discuss testing with their physicians as well.
That is why I consider Lp(a) one of the most useful “once in adulthood” blood tests we have added to routine cardiovascular risk assessment.
3. ApoB: How Many Atherogenic Particles Are Actually Circulating?
Another test receiving increasing attention is Apolipoprotein B, or ApoB.
This is where people sometimes become confused by LDL cholesterol.
Think of it this way:
LDL-C tells us how much cholesterol is being carried.
ApoB gives us a better estimate of how many atherogenic particles are doing the carrying.
These are not always the same thing.
Two people may have similar LDL-C results but different numbers of circulating atherogenic particles.
That difference can matter.
Who needs ApoB?
I do not believe every healthy person needs an enormous panel of advanced cholesterol tests.
ApoB is particularly useful in selected patients—for example, when there is diabetes, elevated triglycerides, established cardiovascular disease, or when LDL-C has already become quite low but we suspect there may still be residual lipoprotein-related risk.
The 2026 guideline specifically recognizes a role for ApoB in these situations.
What does a high ApoB mean?
It means:
There may be more atherogenic particles circulating than the conventional LDL-C number alone suggests.
It does not mean:
“I have a blockage and need an angiogram.”
Again, this is a risk marker—not an angiogram in a test tube.
4. HbA1c: Don’t Ignore the Sugar Side of Heart Disease
Cardiovascular prevention is not just about cholesterol.
Diabetes is one of the most important drivers of coronary artery disease.
HbA1c gives us an estimate of average blood glucose over approximately the previous two to three months.
The commonly used ranges are:
- Below 5.7%: generally considered normal
- 7–6.4%: prediabetes
- 5% or above: in the diabetes range, with diagnosis made according to standard confirmation criteria and clinical circumstances
Prediabetes does not mean that somebody will inevitably develop coronary disease. But it is associated with increased cardiovascular risk and frequently travels with other problems—abdominal obesity, high triglycerides, hypertension and eventually diabetes.
Why does this matter?
Because I would not consider cardiovascular prevention complete if we aggressively treat LDL while ignoring worsening glucose metabolism.
Heart disease rarely respects the artificial boundaries we create between “cholesterol,” “diabetes,” “blood pressure” and “weight.”
They interact.
5. hs-CRP: When Inflammation Adds Information
Atherosclerosis is not simply cholesterol accumulating inside a pipe.
Inflammation plays an important role in plaque biology.
High-sensitivity C-reactive protein, or hs-CRP, is one way of measuring low-grade systemic inflammation.
But hs-CRP needs to be interpreted carefully.
It is not specific to the heart.
A viral infection, inflammatory illness and many other conditions can temporarily raise it.
So an isolated high hs-CRP does not mean:
“My coronary plaques are inflamed.”
That would be an overinterpretation.
When is it useful?
In selected patients whose cardiovascular risk remains uncertain, a persistently elevated hs-CRP can provide additional information.
The 2026 ACC/AHA guideline identifies hs-CRP ≥2 mg/L on more than one occasion as a risk-enhancing factor. In borderline-risk patients, when there is no other obvious reason for the elevation, this can influence decisions about preventive treatment.
I would not interpret hs-CRP taken during a significant acute illness as though it were a pure measure of cardiovascular inflammation.
Context matters.
What About Troponin and BNP?
Patients frequently ask whether they should include troponin or BNP/NT-proBNP in a “complete heart blood test.”
Usually, the answer is no.
They answer different questions.
Troponin
Troponin is a marker of heart muscle injury.
It is critically important when we are evaluating somebody with possible acute coronary syndrome or another condition causing myocardial injury.
It is not a routine screening test for hidden coronary blockages in an otherwise well person.
An elevated troponin also does not automatically mean a heart attack; it has to be interpreted in the clinical context.
BNP and NT-proBNP
These biomarkers are primarily useful when assessing cardiac wall stress and heart failure.
Again, they are valuable tests when ordered for the right reason.
They are not general screening tests to determine whether your coronary arteries are blocked.
So Which Tests Should I Actually Know About?
Let me put it plainly.
If you take only one action after reading this article, get your Lp(a) checked once in your lifetime.
Beyond that, here is how I would prioritize things for most adults:
For everyone
- A standard lipid panel (LDL-C, HDL-C, triglycerides, total cholesterol)
- Lp(a), once
- HbA1c or fasting glucose
For selected patients
- ApoB — if you have diabetes, elevated triglycerides, known cardiovascular disease, or an LDL-C that already looks good but something still feels unexplained
- hs-CRP — if your risk genuinely sits in a borderline zone and there is no obvious reason, such as a recent infection, for it to be elevated
Not for routine screening
- Troponin, BNP and NT-proBNP — order these when there is a clinical reason, not simply because they sound like “heart tests”
None of these tests, alone or together, replace a conversation with your physician about your actual risk.
They are inputs into that conversation—not a verdict.
A Special Point for Indians and South Asians
This deserves particular attention.
South Asians have a substantial burden of premature cardiovascular disease, and the 2026 ACC/AHA guideline specifically recognizes South Asian ancestry as a cardiovascular risk-enhancing factor.
This does not mean every Indian needs twenty sophisticated blood tests or a CT scan.
It does mean we should be cautious about being falsely reassured by statements such as:
“My cholesterol is normal, so I don’t have to worry about my heart.”
Family history matters.
Diabetes matters.
Blood pressure matters.
Smoking matters.
Lp(a) matters.
Body composition and metabolic health matter.
And symptoms certainly matter.
A single “normal” number should never replace an assessment of the whole patient.
Blood Tests Still Cannot Tell You Whether an Artery Is Blocked
This may be the most important section of this article.
Suppose your LDL is excellent.
Your Lp(a) is normal.
Your HbA1c is normal.
Your hs-CRP is low.
Can I therefore tell you that there is no plaque in your coronary arteries?
No.
These tests describe risk and biology.
They do not show us the coronary anatomy.
When clinically appropriate, tests such as a coronary calcium scan can help refine cardiovascular risk, while coronary CT angiography or invasive coronary angiography can provide anatomical information about coronary plaque and narrowing.
These tests are not interchangeable either.
A calcium score helps us quantify calcified coronary atherosclerotic burden and refine risk. It does not tell us everything that a coronary CT angiogram or invasive angiogram can tell us.
The right test depends on the question we are trying to answer.
Most importantly:
A normal blood report should never be used to dismiss convincing cardiac symptoms.
What If You Already Have a Blockage—or a 100% Blocked Artery?
This is where the distinction becomes even more important.
If an angiogram has already shown coronary disease, blood tests such as LDL-C, ApoB, Lp(a) and HbA1c help answer:
Why is this patient at risk of developing more plaque or having another cardiovascular event, and what can we modify?
They do not answer:
Can this particular blockage be treated?
And they certainly cannot tell us:
Should this particular blockage be opened?
Those are different questions.
In a patient with complex coronary disease—and particularly a chronic total occlusion, or CTO, where an artery has been completely blocked for a prolonged period—the decision requires much more than a cholesterol result.
We consider the patient’s symptoms, coronary anatomy, ischemia where relevant, heart function, the amount of viable myocardium, other available treatment options, procedural complexity and, most importantly, what we are trying to achieve for that particular patient.
A beautiful blood report does not make a 100% blockage disappear.
Equally, simply finding a 100% blockage does not automatically mean it should be opened.
Good cardiology is about putting the biology, anatomy and patient together.
My Bottom Line
If you have never had an Lp(a) checked, it is reasonable to discuss getting it measured at least once.
Know your LDL-C.
If you have diabetes, high triglycerides, known cardiovascular disease or unusually complicated lipid results, ask whether ApoB would add useful information.
Know your HbA1c.
Use hs-CRP selectively, not as a fashionable “inflammation test” ordered without context.
But above all, remember this:
Treat your risk factors—but don’t mistake a good blood report for a picture of your coronary arteries.
They answer different questions.
And understanding that difference can prevent both unnecessary anxiety and dangerous reassurance.
References
[1] Blumenthal RS, Morris PB, et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia. Circulation / Journal of the American College of Cardiology. 2026. https://www.ahajournals.org/doi/10.1161/CIR.0000000000001423
[2] American Heart Association. Top Things to Know: 2026 Guideline on the Management of Dyslipidemia. 2026. https://professional.heart.org/en/science-news/2026-guideline-on-the-management-of-dyslipidemia
[3] American Diabetes Association Professional Practice Committee. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2026. Diabetes Care. 2026. https://diabetesjournals.org/care/article/49/Supplement_1/S27/163926/2-Diagnosis-and-Classification-of-Diabetes
[4] Reyes-Soffer G, Ginsberg HN, Berglund L, et al. Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease. Arteriosclerosis, Thrombosis, and Vascular Biology. 2022. https://www.ahajournals.org/doi/10.1161/ATV.0000000000000147
This article is educational and does not replace individualized medical advice.
